The ERBB network: at last, cancer therapy meets systems biology

Autophosphorylation of the carboxyl‐terminal domain is not required for oncogenic transformation by lung‐cancer derived EGFR mutants

“…Epidermal growth factor receptor (EGFR) is a member of the ErbB family consisting of closely related receptor tyrosine kinases including ErbB2, ErbB3 and ErbB4 1. Aberrant activation of EGFR is among the most common oncogenic driving events in human cancer, which is mediated largely through different classes of genomic alterations within the EGFR gene 2.…”

An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib

“…These receptors are activated by either homo-or heterodimerization upon ligand binding resulting in phosphorylation of specifi c tyrosine residues. [ 20,21 ] The overexpression of EGFR and HER2 in breast cancer, is associated with poor prognoses. [ 20,22,23 ] Gefi tinib is used for treatment of EGFR and HER2 overexpressing breast cancers.…”

Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab

“…These receptors are activated on the cell membrane by the binding of specific ligands, which leads to receptor homo-and heterodimerization with other HER family members. Dimerization of HER family receptors results in the activation of each receptor's tyrosine kinases, and subsequently the activation of multiple downstream effector molecules (1,2). Specifically, EGFR regulates the MAPK and PI3K/AKT signaling pathways, both of which have been associated with increased cellular proliferation, survival, angiogenesis, and invasion (3).…”